ALNYLAM PHARMACEUTICALS, INC. Form 8-K September 26, 2012

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 26, 2012 (September 25, 2012)

Alnylam Pharmaceuticals, Inc.

 $(Exact\ Name\ of\ Registrant\ as\ Specified\ in\ Charter)$

Delaware (State or Other Jurisdiction

000-50743 (Commission 77-0602661 (IRS Employer

of Incorporation) File Number) Identification No.)

Edgar Filing: ALNYLAM PHARMACEUTICALS, INC. - Form 8-K


300 Third Street, Cambridge, MA
(Address of Principal Executive Offices)

Registrant s telephone number, including area code: (617) 551-8200

(Zip Code)

Not applicable

(Former Name or Former Address, if Changed Since Last Report)



- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: ALNYLAM PHARMACEUTICALS, INC. - Form 8-K

Item 8.01. Other Events.

On September 25, 2012, Alnylam Pharmaceuticals, Inc. (the Company) filed a complaint in the Federal Court of Canada against Tekmira Pharmaceuticals Corporation (Tekmira) for patent infringement arising from Tekmira s activities providing lipid nanoparticle-formulated small interfering RNA (siRNA) molecules to a pharmaceutical collaborator, as well as Tekmira sown target research and validation activities. As described in the complaint, Tekmira has allegedly infringed the issued patent, CA Patent No. 2,359,180, related to siRNA technology.

The Company is seeking judgment that Tekmira has infringed the patent at issue, a permanent injunction enjoining the infringing activities, damages, and costs and expenses, including attorneys fees.

Edgar Filing: ALNYLAM PHARMACEUTICALS, INC. - Form 8-K

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 26, 2012

ALNYLAM PHARMACEUTICALS, INC.

By: /s/ Michael P. Mason Michael P. Mason

Vice President, Finance and Treasurer